Ralph Devitto Archives - American Brain Tumor Association

ABTA President and CEO Ralph A. DeVitto Announces Retirement

Chicago, IL (May 6, 2024)—The American Brain Tumor Association (ABTA) announced that President and CEO Ralph A. DeVitto has informed the Board of Directors of his intention to retire from ABTA in January 2025, after leading the organization for nearly seven years.

American Brain Tumor Association Announces New Board of Directors Officers and Members

Meet the ABTA’s newest Board Members, Laura Aguilar, MD, PhD, and Charles (Chad) Schafer, JD.

Minh Nguyen at the 2023 SNO Annual Meeting

Annual SNO Meeting Fosters Unprecedented Collaboration

Read our top takeaways from the Society for Neuro-Oncology (SNO) Annual Meeting, the world’s largest gathering of neuro-oncology experts.

Beth Kassab, ABTA volunteer, with Christie and Bryan Bishop at the 2023 National Conference

Brain Tumor Survivor Shares Top Three National Conference Takeaways

After losing her husband to GBM in 2022 and receiving her own diagnosis, survivor Beth Kassab didn’t know what to expect attending the largest brain tumor conference in Chicago. Read Beth’s top takeaways:

ABTA Announces $50-Million Fundraising Campaign to Accelerate Research, Improve Lives of Brain Tumor Patients

A champion of the brain tumor community for 50 years running, the American Brain Tumor Association (ABTA) has launched its most ambitious undertaking yet – a five-year, $50-million fundraising campaign called Meet Hope Head On.

The Meet Hope Head On campaign will focus on three pillars: tripling the ABTA’s research investment, doubling the number of patients served, and doubling federal funding for brain tumor research. Throughout its 50-year history, the ABTA has provided vital seed money to fund high-risk, high-reward research grants which have contributed to significant breakthroughs in treating brain tumors by many of the country’s leading researchers.

First Targeted Therapy for Glioma Headed for FDA Approval

A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”

American Brain Tumor Association Announces New Board of Directors Chair, Officers and Member

Meet the newly-appointed ABTA Board Chair and Member and discover what they’re hopeful for in their new roles.

American Brain Tumor Association Partners with Brain Tumour Foundation of Canada on Low-Grade Glioma Research

The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.